Table 1.
Clinical characteristics and laboratory features of patients with SpA or RA and healthy controls
|
HC (n = 88) |
SpA (n = 165) |
RA (n = 71) |
P | |
| Age (years) | 44.4 ± 0.8 (20 to 62) |
42.9 ± 1.1 (18 to 75) |
59.1 ± 1.4 (19 to 80) |
< 0.0001 (KW) SpA vs HC (MW): P = 0.28 RA vs SpA and RA vs HC (MW): P < 0.0001 |
| Sex | 56 M/16 F | 121 M/44 F | 27 M/44 F | SpA vs HC vs RA: P < 0.0001 (χ2) SpA vs HC: P = 0.9 RA vs SpA and RA vs HC: P < 0.0001 (χ2) |
| Disease duration (years) | 9.2 ± 0.6 (0.5 to 35) |
10.2 ± 1.1 (0.5 to 40) | 0.5 (MW) | |
| Extra-articular manifestations (%) | 35/165 (21) | 26/71 (36.6) | ||
| Peripheral arthritis (%) | 46/165 (27.8) | |||
| BASDAI (0 to 100) | 35.9 ± 2.2 (0.4 to 94) |
|||
| BASFI (0 to 100) | 41.2 ± 2.9 (0 to 92) |
|||
| Swollen joint count (0 to 28) | 7.2 ± 0.8 (0 to 22) | |||
| Tender joint count (0 to 28) | 4.7 ± 0.8 (0 to 28) | |||
| HAQ (0 to 3) | 1.5 ± 0.1 (0 to 3) | |||
| HLA-B27 (%) | 145 (87.8) | |||
| Rheumatoid factors (%) | 64/71 (90) | |||
| ESR (mm/h) | 28.2 ± 2.1 (1 to 163) | 30.3 ± 3.1 (1 to 125) | 0.3 (MW) | |
| CRP (mg/l) | 25.1 ± 3.2 (0 to 350) | 22.3 ± 3.5 (1 to 132) | 0.8 (MW) |
Results are expressed as mean ± standard error of the mean (range). The Kruskal-Wallis test was used to compare age, disease duration, ESR, and CRP in the three groups. Then, Mann-Whitney U-test was used to calculate the exact P values between two groups.
BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; HAQ = Health Assessment Questionnaire; HC = healthy controls; HLA = Histocompatibility Leukocyte Antigen; KW = Kruskal-Wallis; MW = Mann-Whitney; NS = not significant; RA = rheumatoid arthritis; SpA = spondylarthropathie; χ2 = chi-squared test.